Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD)
fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
Gilead Sciences (GILD) appears undervalued with strong profitability, a solid dividend, and moderate growth, offering a compelling case for value investors.
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention. Management attributed the 7% year-over-year HIV growth to robust demand for Biktarvy and Descovy, along with effective commercial execution. CEO Daniel O’Day highlighted, “Biktarvy continues to lead in share in major markets around the world,” and described Descovy’s quarter as its “strongest ever,” supported by heightened awareness and growing use of pre-exposure prophylaxis (PrEP). The company also noted that new product launches, particularly Yeztugo, contributed to positive momentum, while declines in Veklury sales due to reduced COVID-19 hospitalizations partially offset gains in the base business.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of strong corporate earnings, sustained momentum in the technology sector, and a perceived easing of anxieties related
The second quarter 2025 earnings season has largely concluded, delivering a powerful shot of optimism to the financial markets. Against a backdrop of persistent economic uncertainties and geopolitical tensions, a surprising number of U.S. corporations have not only met but significantly exceeded analyst expectations for both earnings and revenue.
The second quarter of 2025 has largely concluded as a period of unexpected strength for U.S. corporations, with a significant number of companies not only meeting but exceeding analyst expectations. This positive trend has injected a renewed sense of optimism into the financial markets, showcasing the resilience of various
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and broad gains among the Magnificent Seven fueled the rally.
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD)
jumped 8.7% in the morning session after the company reported second-quarter 2025 results that topped Wall Street's expectations and raised its full-year financial guidance. The biopharmaceutical company posted revenue of $7.08 billion and adjusted earnings per share (EPS) of $2.01, beating analysts' consensus estimates for both figures. Buoyed by the results, Gilead raised its full-year adjusted EPS guidance to a midpoint of $8.10. While it also slightly lifted its full-year revenue guidance to $28.5 billion, this figure remained just below what analysts were projecting. Investors appeared to focus on the earnings beat and the improved profit outlook for the year, which outweighed the more cautious signal on revenue.
